{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.9","upperLimit":"32.6","value":"25"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"4.0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"90"}],"units":"Participants"}],"description":"Molecular remission was defined as a minimal residual disease (MRD)-negative result at the end of treatment (assessment that occurred between 56 days and 6 months of last treatment). Molecular remission was assessed for all patients using a blood sample. Additionally, a bone marrow sample was obtained from patients whom the investigator assumed to have a complete response, consistent with the IWCLL guidelines. A combined analysis of blood and bone marrow results was conducted. A patient was considered MRD negative if result was less than 1 chronic lymphocytic leukemia (CLL) cell in 10000 leukocytes (MRD value \\< 0.0001) based on the method of allele specific polymerase chain reaction (ASO-PCR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \\[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).","id":"OG000","title":"Obinutuzumab + Chlorambucil (GClb)"},{"description":"Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.","id":"OG001","title":"Chlorambucil (Clb)"}],"paramType":"NUMBER","populationDescription":"Participants from the Intent-to-treat population (all randomized participants) with data available for analysis. Participants who did not reach the 3 month Follow-up visit at the time of the clinical cutoff are excluded.","reportingStatus":"POSTED","timeFrame":"Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)","title":"Percentage of Participants With Molecular Remission at the End of Treatment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}